For how we live.
A phase 1 trial in 288 Chinese children found the experimental injectable vaccine well tolerated and able to raise antibodies. It measured immune response, not whether it prevents disease.
A national database of ~90% of public facilities found all-cause diarrhoea incidence in under-fives dropped 50% and hospitalisations 58% after 2020, with no rise in intussusception.
A Global Burden of Disease analysis of 204 countries finds 15.7 million children received no DTP dose in 2023, more than half of them in eight countries, and only one of three target vaccines on track for 2030.